During the last session, Intellia Therapeutics Inc (NASDAQ:NTLA)’s traded shares were 5.76 million, with the beta value of the company hitting 2.13. At the end of the trading day, the stock’s price was $9.60, reflecting an intraday gain of 0.21% or $0.02. The 52-week high for the NTLA share is $28.18, that puts it down -193.54 from that peak though still a striking 38.54% gain since the share price plummeted to a 52-week low of $5.90. The company’s market capitalization is $994.40M, and the average trade volume was 4.34 million shares over the past three months.
Intellia Therapeutics Inc (NTLA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.62. NTLA has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 13 recommend a Buy rating for it.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Intellia Therapeutics Inc (NTLA) registered a 0.21% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.21% in intraday trading to $9.60, hitting a weekly high. The stock’s 5-day price performance is 14.70%, and it has moved by 5.96% in 30 days. Based on these gigs, the overall price performance for the year is -61.83%.
The consensus price target of analysts on Wall Street is $17.5, which implies an increase of 45.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $26 respectively. As a result, NTLA is trading at a discount of -170.83% off the target high and 6.25% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.04%. While earnings are projected to return 20.55% in 2025, the next five years will return 31.48% per annum.
NTLA Dividends
Intellia Therapeutics Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Intellia Therapeutics Inc insiders own 4.99% of total outstanding shares while institutional holders control 97.15%, with the float percentage being 102.25%. ARK INVESTMENT MANAGEMENT LLC is the largest shareholder of the company, while 415.0 institutions own stock in it. As of 2024-06-30, the company held over 11.6 million shares (or 11.9575% of all shares), a total value of $259.51 million in shares.
The next largest institutional holding, with 9.6 million shares, is of BLACKROCK INC.’s that is approximately 9.897% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $214.79 million.
